neo soma semaglutide Novo Nordisk's shortage officially concludes in the US, spelling major threat for weight loss drug compounders First Time Semaglutide - Neo

Innate immune system as a first line of defense includes macrophages, natural killer (NK) cells, phagocytes and neutrophils (6)

The medication also influences dopamine and serotonin pathways in the central nervous system, neurotransmitters directly tied to energy, mood, and motivation

Note: Ozempic , Mounjaro , Victoza , and metformin are not FDA-approved to treat obesity or for weight loss

She researched heavily, questioning whether using a GLP-1 would feel like a shortcut

Demand has been so high, both drugs are now listed in short supply on the Federal Drug Administrations drug shortage website

Novo Nordisk reported net sales of $43.27 billion in 2025, with its obesity and weight-loss drugs accounting for a large percentage of its growth